Physician profile
Danny W Giles
NPI 1932261450
$528.49
in general payments reported to CMS, 2019-2025
14 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.95 · 2022: $34.80 · 2023: $112 · 2024: $182 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $139.50 | 2024-2025 | Gel-One Cross-Linked Hyaluronate, Mobi-C |
| Pacira Pharmaceuticals Incorporated | $63.56 | 2023-2025 | Iovera, Zilretta, Exparel |
| Horizon Therapeutics Plc | $44.29 | 2023 | Krystexxa |
| Vertex Pharmaceuticals Incorporated | $38.83 | 2024-2025 | |
| Ethicon US, LLC | $37.75 | 2025 | Stratafix, Ethicon |
| Organogenesis INC. | $35.04 | 2023-2024 | Puraply |
| Highridge Medical LLC | $31.67 | 2024 | Vital, Gel One-Spine, Mobi-C Plug & Fit US |
| Bioventus LLC | $31.38 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Pacira Therapeutics, INC. | $24.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.05 | 2019 | |
| Stryker Corporation | $19.55 | 2022 | |
| Omnilife Science, INC | $14.74 | 2019 | |
| Abbott Laboratories | $13.69 | 2023 | Proclaim |
| Smith+Nephew, INC. | $13.28 | 2023 | Evos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Giles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.